Ascendis Pharma A/S Sponsored ADR (ASND)

Ascendis Pharma's stock experienced takeover speculation in December 2025 and January 2026. The company reported a net loss of €34 million for Q4 2025 and €228 million for the full year 2025, with Q4 revenue reaching €248 million and full-year revenue doubling to €720 million. The FDA approved YUVIWEL in March 2026, followed by a stock decline due to profit-taking. New clinical data from trials for TransCon CNP and TransCon hGH were presented in March 2026.

Information regarding the specific demand seasonality for Ascendis Pharma A/S products and services is not publicly available.

Ascendis Pharma A/S is a biopharmaceutical company utilizing its TransCon™ technology platform to develop long-acting prodrug therapies, focusing on endocrinology and oncology. Key products include SKYTROFA® for pediatric and adult growth hormone deficiency, YORVIPATH® for chronic hypoparathyroidism, and YUVIWEL® for children with achondroplasia. The company is also expanding into oncology with therapies like TransCon TLR7/8 Agonist and TransCon IL-2 β/γ.

Ascendis Pharma A/S is headquartered in Copenhagen, Denmark, with facilities in Europe and the United States. Its products are available in over 30 countries outside the U.S., with launches planned in 10 more countries by the end of 2026. The company has partnerships with VISEN Pharmaceuticals for Greater China and Teijin Limited for Japan.

Ascendis Pharma maintains a positive brand reputation due to its TransCon™ technology and successful clinical development. The company has a "Strong Buy" consensus from financial institutions, with analysts highlighting the platform's versatility. Positive clinical trial results and regulatory approvals have contributed to a favorable perception.

Ascendis Pharma A/S has a strong institutional ownership concentration, with 358 institutional owners holding 66,150,038 shares as of March 27, 2026. Institutional ownership is between 106.90% and 108.06% as of March 31, 2025, while insiders hold 0.78% and retail investors hold 0.00%. Major institutional owners include RA Capital Management, L.P., Westfield Capital Management Co Lp, Avoro Capital Advisors LLC, Fmr Llc, and Janus Henderson Group Plc.